Opus Genetics has secured FDA alignment on the pivotal Phase 3 design of OPGx‑LCA5, an investigational gene therapy for LCA5‑associated childhood blindness, supporting a potential BLA based on six‑month efficacy data.
Written By: Shaik Yasmeen, PharmD
Reviewed By: Pharmacally Editorial Team
Opus Genetics has reached regulatory alignment with the U.S. Food and Drug Administration (FDA) on the pivotal Phase 3 clinical trial design for OPGx-LCA5, its investigational gene therapy for LCA5-associated inherited retinal disease (IRD), an ultra-rare cause of severe childhood blindness. The agreement, achieved through a Type B Rare Disease Evidence Principles (RDEP) meeting, establishes the registrational pathway for the program and supports a potential Biologics License Application (BLA) based on six-month efficacy data.
According to the FDA meeting minutes, the Phase 3 study will enroll eight participants capable of completing microperimetry testing, with both eyes treated. Each participant will undergo a six-month run-in period, serving as their own natural history control before treatment. Seven of the eight planned participants have already entered the run-in phase, and Opus Genetics expects to begin dosing in the fourth quarter of 2026.
Gene Therapy Targets a Severe Form of Childhood Blindness
OPGx-LCA5 is an AAV8-mediated gene therapy that delivers a functional LCA5 gene to retinal cells in patients with biallelic LCA5 mutations, which cause a severe early-onset inherited retinal dystrophy known as Leber congenital amaurosis (LCA5). The disease leads to profound vision loss during childhood and currently has no approved treatment.
Research has shown that retinal structure may remain partially preserved despite significant visual impairment in these patients, providing a therapeutic opportunity for gene replacement to restore retinal function.
Phase 3 Design Supported by Early Clinical Results
The pivotal trial will use mean improvement of at least 7 decibels (dB) in retinal sensitivity across the central 16 microperimetry test loci as its primary efficacy endpoint. The study has been powered at more than 90% to detect this treatment effect.
The endpoint is supported by findings from the ongoing Phase 1/2 clinical trial, where participants able to complete microperimetry demonstrated an average improvement of approximately 10.5 dB in retinal sensitivity.
Clinical data generated so far have also shown encouraging functional outcomes. Pediatric participants experienced substantial gains in cone-mediated vision, while adults demonstrated durable improvements in cone sensitivity and visual function through 18 months of follow-up. The therapy has remained well tolerated, with no ocular serious adverse events or dose-limiting toxicities reported.
FDA Opens a Potential Accelerated Regulatory Path
A key outcome of the FDA meeting is the agency’s indication that Opus Genetics may submit a BLA after the six-month primary efficacy analysis, provided the results are sufficiently compelling. Long-term 12-month durability data could then be submitted during the FDA’s review of the application rather than before filing, potentially shortening the overall development timeline.
Chief Executive Officer George Magrath, MD, said the FDA alignment provides a clear regulatory roadmap for the program and allows the company to move toward Phase 3 dosing later this year. He also noted that OPGx-LCA5 may qualify for a Rare Pediatric Disease Priority Review Voucher, which could represent an additional strategic asset if the therapy receives approval.
Co-founder Jean Bennett, MD, PhD, emphasized the significant unmet medical need in LCA5-associated inherited retinal disease, noting that affected children currently have no approved treatment options. She said the continued collaboration with the FDA supports rapid advancement of the program for patients and families.
Regulatory Path Forward
OPGx-LCA5 has received Rare Pediatric Disease, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA and is also enrolled in the agency’s Rare Disease Evidence Principles (RDEP) program. With enrollment nearly complete and dosing expected to begin in the fourth quarter of 2026, the registrational study represents the final clinical step toward a potential first approved gene therapy for LCA5-associated inherited retinal disease.
Reference
About the Writer
Shaik Yasmeen (LinkedIn) is a Pharm.D graduate with interests in clinical pharmacy, pharmacovigilance, and medical writing. She has gained experience through hospital clinical postings, patient case reviews, case presentations, and literature evaluation. Passionate about evidence-based healthcare, she is committed to creating accurate and engaging medical content while continuously expanding her professional knowledge.